Jefferies assumed coverage of Scholar Rock (SRRK) with a Buy rating and $50 price target The firm expects the company’s apitegromab to be approved in spinal nuscular atrophy with a broad label. However, the September 22 FDA action date could be delayed to Q1 due to procedural observations from a recent FDA site inspection, the analyst tells investors in a research note. Jefferies models peak sales of $1.8B for the drug.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock publishes SAPPHIRE trial data in The Lancet
- Positive Outlook on Scholar Rock Holdings Due to Innovative Therapies and Strategic Advancements
- Scholar Rock’s Optimistic Earnings Call Highlights Progress
- Scholar Rock Reports Q2 2025 Progress and Financials
- Optimistic Buy Rating for Scholar Rock Amid Apitegromab’s Promising FDA Review and Market Expansion Potential